Lite Strategy, Inc. (LITS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Lite Strategy, Inc. (LITS) has a cash flow conversion efficiency ratio of -0.040x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.51 Million) by net assets ($112.27 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Lite Strategy, Inc. (LITS) balance sheet quality index to measure how much of total assets are equity-financed.
Lite Strategy, Inc. - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how Lite Strategy, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check LITS cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Lite Strategy, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lite Strategy, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Loop Industries Inc
NASDAQ:LOOP
|
0.286x |
|
Playside Studios Ltd
AU:PLY
|
0.100x |
|
Sentien Printing Factory Co Ltd
TWO:8410
|
0.079x |
|
BioSmart Co.Ltd
KQ:038460
|
0.042x |
|
Nexam Chemical Holding AB
ST:NEXAM
|
-0.024x |
|
George Kent (Malaysia) Bhd
KLSE:3204
|
0.037x |
|
Concraft Holding Co Ltd
TW:4943
|
0.011x |
|
Radana Bhaskara Finance Tbk
JK:HDFA
|
-0.240x |
Annual Cash Flow Conversion Efficiency for Lite Strategy, Inc. (2021–2025)
The table below shows the annual cash flow conversion efficiency of Lite Strategy, Inc. from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Lite Strategy, Inc..
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $16.93 Million | $-20.84 Million | -1.231x | +19.46% |
| 2024-06-30 | $33.02 Million | $-50.47 Million | -1.529x | +28.28% |
| 2023-06-30 | $24.62 Million | $-52.48 Million | -2.131x | -129.18% |
| 2022-06-30 | $52.41 Million | $-48.75 Million | -0.930x | -43.93% |
| 2021-06-30 | $49.47 Million | $-31.96 Million | -0.646x | -- |
About Lite Strategy, Inc.
Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025. Lite Strategy, Inc. was incorporated in 2000 and is based in San Diego, California.